NEW YORK (GenomeWeb News) – Quest Diagnostics this week said that it completed its acquisition of full-service commercial laboratory firm Solstas Lab Partners Group and its subsidiaries for $570 million. In connection with the deal, Quest raised its guidance for full-year 2014. Revenues are now expected to grow between 2 percent and 4 percent, compared to full-year 2013. It previously said 2014 revenue was anticipated to be flat to down 2 percent year over year, excluding the Solstas purchase.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.